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a  b  s  t  r  a  c  t
PCR  for antigen  receptor  gene  rearrangements  (PARR)  analysis  is  being  increasingly  used to assist  diag-
nosis  of canine  lymphoma.  In this  study,  PARR was  carried  out on  consecutive  samples  received  as  part
of routine  diagnostic  practice  from  271  patients:  195  with  lymphoid  malignancies,  53 with  reactive  con-
ditions  and  23  with  other  neoplasms.  Initially,  published  primer  sets were  used but later  minor  primer
modiﬁcations  were  introduced  and  primers  were  rationalised  to  give  a PARR  panel  that  provides  a  good
compromise  between  sensitivity  and  cost.  Results  were  compared  to  diagnoses  made  by  histology  or
cytology,  coupled  with  immunophenotyping  by ﬂow  cytometry  or immunohistochemistry  where  pos-
sible. After  exclusion  of 11  poor  quality  samples,  230/260  (88%)  gave  a clear result  with  162/163 (99%)
of  samples  classiﬁed  as  clonal  and  56/67  (84%)  classiﬁed  as  polyclonal  giving  results  concordant  withlassiﬁcation
ARR
eneScan
the  cytological/histological  diagnosis.  Among  30 samples  with  equivocal  results,  21  had  clonal  peaks  in
a polyclonal  background  and  nine  showed  little  ampliﬁcation.  These  were  from  patients  with  a  range
of  neoplastic  and  non-neoplastic  conditions  emphasising  the  need  to interpret  such  results  carefully  in
concert with  other  diagnostic  tests.  The  combination  of  primer  sets  used  in  this  study  resulted  in a  robust,
highly  speciﬁc  and sensitive  assay  for detecting  clonality.
©  2016  The  Authors.  Published  by  Elsevier  B.V.  This  is  an open  access  article  under  the  CC  BY  license. Introduction
PCR for antigen receptor gene rearrangements (PARR) is increas-
ngly being used in the diagnostic setting as a means of assessing
lonality in samples with a differential diagnosis of canine
ymphoma. Several different primers sets for ampliﬁcation of rear-
anged immunoglobulin heavy chain (IgH) and T-cell receptor
amma  (TCR) genes have been described (Vernau and Moore,
999; Burnett et al., 2003; Tamura et al., 2006; Yagihara et al.,
007; Gentilini et al., 2009; Chaubert et al., 2010; Keller and Moore,
012). Primer design was initially based on cDNA sequences gen-
rated by 5′ rapid ampliﬁcation of cDNA ends from normal canine
pleen (Vernau and Moore, 1999; Burnett et al., 2003). High rates
f detection of clonality were reported despite the use of a small
umber of primer sets, suggesting that some gene segments are
∗ Corresponding author.
E-mail address: e.waugh.1@research.gla.ac.uk (E.M. Waugh).
ttp://dx.doi.org/10.1016/j.vetimm.2016.10.008
165-2427/© 2016 The Authors. Published by Elsevier B.V. This is an open access article u(http://creativecommons.org/licenses/by/4.0/).
commonly rearranged or that dogs have a more limited recom-
binatorial repertoire than humans. Following publication of the
canine genome (Lindblad-Toh et al., 2005), primers were modiﬁed
and added to provide better gene coverage and improve sensitivity
(Tamura et al., 2006; Yagihara et al., 2007; Chaubert et al., 2010);
however, full annotations of the TCR and IgH loci were not pub-
lished until 2009 and 2010, respectively (Massari et al., 2009; Bao
et al., 2010). Studies prior to this did not consider all described
segments, with only a single publication using a comprehensive
PCR strategy addressing all known gene segments, and this only
for TCR (Keller and Moore, 2012). It is therefore unlikely that
currently used primer sets will detect all antigen receptor gene
rearrangements, resulting in sub-optimal sensitivity.
While assay sensitivity generally appears good, with detection
of clonality in up to 98% of canine lymphomas (Gentilini et al.,
2009), most PARR studies have tested primer sets on selected, well-
deﬁned samples from conﬁrmed lymphoid malignancies. In the
clinic, however, PARR is most useful in cases where there is some
ambiguity over the morphological diagnosis. The performance of
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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these assays with a range of diagnostic samples, including those
which are difﬁcult to classify with routine methods, remains to be
established. From the limited information available, detection rates
in diagnostic samples appear lower. One laboratory reported sensi-
tivity of 75% using the Burnett primers over one year (Avery, 2009),
while the comprehensive TCR assay yielded concordant results
in only 41 of 60 (68%) clinical samples (Keller and Moore, 2012).
Thus there is scope to increase the accuracy of these assays through
further improvements in primer design. Furthermore, while most
studies have assessed sensitivity, speciﬁcity of the canine assays
has not been widely discussed and most studies have analysed
only a few normal or reactive samples, generally in the initial
set-up phase. Burnett et al. (2003) detected one clonal IgH rear-
rangement (an Ehrlichiosis case) in the analysis of 24 samples from
dogs with various inﬂammatory and non-lymphoproliferative neo-
plastic conditions and Chaubert et al. (2010) observed no clonal
TCR rearrangements in 23 samples from reactive skin conditions.
Although both results suggest that speciﬁcity is good, consistent
with the 94% reported by Avery (2009), this again requires broader
study in clinical samples. While improvements in primer design
should enhance sensitivity and speciﬁcity, a consolidated interpre-
tation of results obtained from critically reviewing PARR results
alongside other diagnostic tests will also impact on the accuracy of
these assays.
The aim of this study was  to reﬁne and rationalise previously
published PARR primer sets in order to produce a panel of assays for
routine use in the diagnostic setting. Initially, multiple published
PARR primers were used to establish baseline sensitivity and speci-
ﬁcity and, subsequently, modiﬁcations to both primer sequences
and primer combinations were made. Assay conditions were also
streamlined to facilitate use in a diagnostic setting. Diagnostic sam-
ples from 271 non-selected, suspected lymphoma patients were
used in these analyses and results compared with morphological
and, where possible, immunophenotypic diagnosis. Estimates of
sensitivity and speciﬁcity were determined, and common difﬁcul-
ties in interpretation identiﬁed.
2. Materials and methods
2.1. Patient and sample characteristics
Clinical samples were collected from untreated patients pre-
senting with suspected lymphoma to the University of Glasgow
Small Animal Hospital, UK. Ethical approval was  obtained from
the Faculty of Veterinary Medicine Ethics and Welfare Commit-
tee, University of Glasgow. Samples consisted of excess material
taken as part of routine evaluations at the time of diagnosis and
were from 195 patients diagnosed with lymphoid malignancies
(172 lymphoma, 11 leukaemia, nine leukaemia/lymphoma, and
three plasma cell tumour), 53 with reactive or inﬂammatory con-
ditions, and 23 with other neoplasms. Samples were either fresh
(ﬁne needle aspirates, biopsies, blood or body ﬂuids), or ﬁxed
(formalin-ﬁxed, parafﬁn-embedded (FFPE) biopsies or acetone-
ﬁxed, May-Grünwald-Giemsa-stained cytological smears). Most
were from lymph node although a range of other tissues was sam-
pled. Patient and sample characteristics are described in Table 1.
A wide range of breeds was represented with Crossbreed and
Labrador the most common across all groups.
With the exception of 18 samples used in initial assay set-up
(5 reactive, 13 lymphoma, all FFPE), all samples were submitted
as non-selected diagnostic samples; analysis and interpretation
were carried out without knowledge of the diagnosis. Diagnoses
were made by cytology or histopathology, with immunophenotyp-
ing by ﬂow cytometry (FC) or immunohistochemistry (IHC) where
possible. For FC, fresh samples were stained with the antibodies
E.M. Waugh et al. / Veterinary Immunology and
Table  2
Antibodies used for ﬂow cytometric analysis of canine samples .
Antibody Cellular Target Clone
Isotype-matched triple
negative FITC/PE/Alexa647
Negative control
CD5-FITC Pan T-cell YKIX322.3
CD21-PE Mature B-cell CA2.1D6
CD45-Alexa647 Pan leukocyte YKIX716.13
CD3-FITC Pan T-cell CA17.2A12
CD4-PE Helper T-cell YKIX302.9
CD8-Alexa647 Cytotoxic T-cell YCATE55.9
CD34-FITC Stem/precursor cells 2E9
CD79a-Alexa647a Pan B-cell HM57
MHC  II-FITC Activated lymphocytes YKIX334.2
MAC387-FITCa Macrophages and monocytes MAC387
CD14-Alexa647 Monocytes TUK4
FC antibodies were sourced from AbD Serotec, with the exception of CD34-FITC
(
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a Antibody targeting an internal epitope (requires permeabilisation).
isted in Table 2 and analysed on a Beckman Coulter FC500 ﬂow
ytometer using CXP software (Beckman Coulter (UK) Ltd, High
ycombe, UK). Erythrocytes were lysed using CalLyse (Life Tech-
ologies Ltd, Paisley, UK). Leukoperm (AbD Serotec, Kidlington, UK)
as used prior to staining for internal antigens. Cell populations
ere gated based on the forward versus side scatter plot and events
egarded as positive where the ﬂuorescence intensity was  greater
han the isotype-matched control for that sample. Where >70% of
ells stained with a single antibody or group of antibodies, the cell
opulation was considered to be of that phenotype. IHC on FFPE
amples was carried out by Veterinary Diagnostic Services, Univer-
ity of Glasgow. Sections were stained with antibodies (all Dako
K Ltd, Ely, UK) against CD3 (T-cell; polyclonal) and either CD79a
B-cell; clone JCB117) or PAX5 (B-cell; clone DAKPax5) in a Dako
utostainer using the Dako EnVision + TM System.
Samples diagnosed as null-cell lymphoma (n = 6) were classi-
ed as lymphoma on morphological grounds but were negative
or CD3 and CD79a/PAX5 by IHC, while one sample diagnosed as
double-labelled lymphoma’ was positive for both CD3 and PAX5.
D34-positive leukaemias (n = 6) were CD34 positive by FC and neg-
tive for other leukocyte antigens. Cases of lymphoma or leukaemia
hat were not subjected to immunophenotyping (n = 48) or where
mmunophenotyping by FC was inconclusive (n = 5) were desig-
ated ‘not otherwise speciﬁed’ (NOS). Plasma cell tumours (n = 3)
ere classiﬁed on the basis of morphology.
.2. PARR
.2.1. Primers
Primers were synthesised according to published sequences
Burnett et al., 2003; Tamura et al., 2006; Yagihara et al., 2007;
entilini et al., 2009; Chaubert et al., 2010), and initially tested
n their original pairings (Tables S1 and S2). Each 5′ primer was
uorescently labelled to facilitate visualisation of products by
eneScan analysis. Primers were subsequently compared to recent
nnotations of the canine IgH (Bao et al., 2010) and TCR (Massari
t al., 2009) variable region loci. For each primer, the number and
ocation of mismatches to the germline sequence of the IgH locus
accession number NW 003726071) or TCR locus (accession num-
er NW 876265), were noted. Mismatches at the 3′ end will have
he most detrimental effect on reaction efﬁciency (Stadhouders
t al., 2010), and so we ensured that all retained primers had a
erfect match in the ﬁve most 3′ bases.Four IgH V segment primers were retained in our PARR panel:
wo IgH framework region 1 (FWR1) primers (918 and 919) were
ncluded to help mitigate the problem of junctional mutation or
omatic hypermutation disrupting the IgH framework region 3 Immunopathology 182 (2016) 115–124 117
(FWR3) primer binding site, and two  IgH FWR3 primers (913 and
916) were retained as they will detect rearrangements in samples
with fragmented DNA. Although some germline V segments have
a perfect match to only one of these primers, most match more
than one of the primers providing some redundancy and mitigat-
ing against false negative results. Two IgH J segment primers are
required to bind to all rearrangements. A single J1-2 primer (914)
was selected from the three tested, and a mismatch in the J3 primer
corrected (915a).
Two  TCR V segment and three J segment primers were included
in our ﬁnal panel. Primer 928 should bind to TCR V2 and V6 seg-
ments. Following correction of four mismatches at the 5′ end of
primer 925 (925a), this primer should bind to V3, V5 or V7 seg-
ments. Primer 930, which should bind the majority of TCR Jx-2
segments, was  modiﬁed to include two mixed bases in the middle
of the primer to allow for sequence variation between segments
(930a). Primer 929 should bind well to Jx-1 segments, except for
segment J5-1 where several mismatches occur at the 3′ end; primer
931 was  therefore designed to match J5-1 more closely. The ﬁnal
PARR primer sequences are listed in Tables 3 and 4.
The ampliﬁability of all DNA samples was  assessed using two
control PCRs. Initially C (128 bp) and -actin (272 bp) primers
were used, and later -actin (125 and 450 bp) primers; ampli-
con sizes correspond to those generated by the PARR primer sets
(Table 4).
2.2.2. PCR and analysis
DNA was  extracted using QIAamp DNA Mini kits or DNA FFPE
Tissue kits (Qiagen Ltd, Manchester, UK). Reactions were performed
in a total volume of 25 l, and contained 100 ng DNA (where
possible), each primer at 250 nM (IDT, Leuven, Belgium) and 1 x
HotStarTaq Plus Master Mix  (Qiagen). Thermal cycling was carried
out on a GeneAmp PCR System 9700 (Applied Biosystems, Life Tech-
nologies). Initially, all primer sets used identical thermal cycling
conditions: 95 ◦C for 5 min, followed by 40 cycles of 95 ◦C for 30 s,
58 ◦C for 30 s, 72 ◦C for 30 s, with a ﬁnal extension of 72 ◦C for 30 min
to facilitate addition of terminal adenosine bases on each PCR prod-
uct. Following optimisation, the annealing temperature for primer
sets 9, 10, 13 and 14 only was  reduced to 50 ◦C consistent with the
low melting temperatures of primers 929 and 931.
Fragment analysis was carried out using GeneScan methodol-
ogy on an ABI 3130×l Genetic Analyser (Applied Biosystems) with a
36 cm capillary length loaded with POP-4 polymer. Products ampli-
ﬁed with primer sets 1 and 4, 2 and 5, and 3 and 6, were combined
prior to fragment analysis; 5′ primers in each combination were
labelled with different ﬂuorochromes so that reaction products
could be distinguished (Table 3).
2.3. Scoring and interpretation
For each individual PARR primer set, results were subjectively
scored as clonal (one or two tall clear peaks with minimal poly-
clonal ampliﬁcation around the base of the peak (Fig. 1B, 1D));
polyclonal (fragments distributed over the size range of the primer
set, either in a Gaussian distribution or a slightly more skewed dis-
tribution (Fig. 1A, C)); dominant peak (one or more clear peaks
visible within a polyclonal distribution (Fig. 2)); poor ampliﬁca-
tion (several small peaks or an irregular polyclonal distribution of
low amplitude (Fig. 3)); or negative (no ampliﬁcation products in
the appropriate size range).
Based on the overall pattern of results with all the PARR primer
sets and the ampliﬁability controls, samples were then assigned to
one of seven categories (Table 5): ‘B-cell clone’; ‘T-cell clone’; ‘clonal
IgH and TCR rearrangement’; ‘reactive’; ‘dominant peak only’; ‘no
peak’; and ‘inadequate sample’. Samples were classed as clonal if a
clear clonal ampliﬁcation product was  seen, even if the larger of the
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Fig. 1. Typical PARR electropherograms showing polyclonal and clonal products. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to
the  web  version of this article.)
Size markers are shown in red. A: Polyclonal products from two separate IgH reactions from the same sample. Fragments are multiplexed for GeneScan analysis with the
shorter FWR3 fragments (blue; primer set 1) on the left and the longer FWR1 fragments (green; primer set 4) on the right. There is a Gaussian distribution of products with
a  peak every three bases. B: Clonal products from a B-cell lymphoma using the same primer sets as in A. A single tall sharp peak is seen. Occasionally a smaller secondary
peak  is seen at the base to the left; this feature is due to overloading of the capillary with product and disappears if the product is diluted. C: Polyclonal TCR products (blue;
primer set 7) exhibiting a Gaussian distribution without a peak every 3 bases. A slightly irregular jagged appearance can sometimes occur. D: Clonal TCR product (primer
set  7) with a similar appearance to the IgH peaks in B.
Fig. 2. Ampliﬁcation of dominant peaks. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
Size  markers are shown in red. A: Dominant peak with TCR primer set 9 (blue) from a T-cell lymphoma. The background polyclonal distribution is skewed towards the peak.
Testing with additional TCR primer sets in the ﬁnal PARR protocol revealed a clonal T-cell population (primer set 10). B: Dominant peaks with IgH primer sets 1 (blue) and
4  (green) from a SMZL. A clear dominant peak is seen with both sets, arising from the same area of the polyclonal distribution, suggesting they represent the same clonal
subpopulation.
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Table  3
PARR primer sets used in the ﬁnal protocol.
Primer set Primer number Target Original primer name Reference Sequence Product size
1 913 IgH V FWR3 CB1 (5′) Burnett (2003) 6-FAM-CAG CCT GAG AGC CGA GGA CAC 85–139 bp
914  IgH J1-2 CB2 (3′) Burnett (2003) TGA GGA GAC GGT GAC CAG GGT
2  916 IgH V FWR3 Tamura F (5′) Tamura (2006) 6-FAM-ACA CGG CCV TGT ATT ACT GT 79–90 bp
914  IgH J1-2 CB2 (3′) Burnett (2003) TGA GGA GAC GGT GAC CAG GGT
3  913 IgH V FWR3 CB1 (5′) Burnett (2003) 6-FAM-CAG CCT GAG AGC CGA GGA CAC 85–145 bp
915a  IgH J3 CB3(3′)a Burnett (2003) TGA GGA CAC GAA GAG TGA GG
4  919 IgH V FWR1 3′ FWR1 (5′) Gentilini (2009) HEX-GCC TCT GGA TTC ACC TTC AG 262–315 bp
914  IgH J1-2 CB2 (3′) Burnett (2003) TGA GGA GAC GGT GAC CAG GGT
5  918 IgH V FWR1 5′ FWR1(5′) Gentilini (2009) HEX-GAG GTG CAG CTG GTG GAG TCT 309–378 bp
914  IgH J1-2 CB2 (3′) Burnett (2003) TGA GGA GAC GGT GAC CAG GGT
6  919 IgH V FWR1 3′ FWR1 (5′) Gentilini (2009) HEX-GCC TCT GGA TTC ACC TTC AG 262–315 bp
915a  IgH J3 CB3(3′)a Burnett (2003) TGA GGA CAC GAA GAG TGA GG
7  928 TCR V2&6 dTCR-Va (5′) Chaubert (2010) 6-FAM-GGC GTG TAC TAC TGC GCT GCC 55–82 bp
930a  TCR Jx-2 dTCR-Jb (3′)a Chaubert (2010) TGT GCC AGG ACC AAD YAC TTT
8  925a TCR V3&5&7 Vb (5′)a Yagihara (2007) HEX-CCA TGT AYT ACT GTG CCT GCT GG 55–82 bp
930a  TCR Jx-2 dTCR-Jb (3′)a Chaubert (2010) TGT GCC AGG ACC AAD YAC TTT
9  928 TCR V2&6 dTCR-Va (5′) Chaubert (2010) 6-FAM-GGC GTG TAC TAC TGC GCT GCC 55–82 bp
929  TCR Jx-1 dTCR-Ja (3′) Chaubert (2010) TAC CTT CTG TAA ATA TCT TGA TC
10  925a TCR V3&5&7 Vb (5′)a Yagihara (2007) HEX-CCA TGT AYT ACT GTG CCT GCT GG 55–82 bp
929  TCR Jx-1 dTCR-Ja (3′) Chaubert (2010) TAC CTT CTG TAA ATA TCT TGA TC
Altered bases are marked in bold. Degenerate bases: V = A, C or G; D = A, G or T; Y = C or T.
a Denotes primer altered slightly from the original published sequence; this is also marked by the sufﬁx ‘a’ in the primer number.
Table 4
Additional PARR primer sets and control assays.
Primer set Primer number Target Primer name Reference Sequence Product size
11 916 IgH V FWR3 Tamura F (5′) Tamura (2006) 6-FAM-ACA CGG CCV TGT ATT ACT GT 79–90 bp
915a  IgH J3 CB3(3′)a Burnett (2003) TGA GGA CAC GAA GAG TGA GG
12  918 IgH V FWR1 5′ FWR1(5′) Gentilini (2009) HEX-GAG GTG CAG CTG GTG GAG TCT 309–378 bp
915a  IgH J3 CB3(3′)a Burnett (2003) TGA GGA CAC GAA GAG TGA GG
13  928 TCR V2&6 dTCR-Va (5′) Chaubert (2010) 6-FAM-GGC GTG TAC TAC TGC GCT GCC 55–82 bp
931  TCR J5-1 J5-1 TTC CTT CTG CAA ATA ATC TTG AT
14  925a TCR V3&5&7 Vb (5′)a Yagihara (2007) HEX-CCA TGT AYT ACT GTG CCT GCT GG 55–82 bp
931  TCR J5-1 J5-1 TTC CTT CTG CAA ATA ATC TTG AT
C  IgM constant region C 1 (5′) Burnett (2003) HEX-TTC CCC CTC ATC ACC TGT GA 128 bp
C  2 (3′) Burnett (2003) GGT TGT TGA TTG CAC TGA GG
-actin  Canine -actin -actin (5′) Gentilini (2009) 6-FAM-ACC ACT GGT ATT GTC ATG GAC TCT G
-actin (3′) AGG TAG TCA GTC AGG TCC CGG 125 bp
-actin (3′) Gentilini (2009) GCT CTT CTC CAG GGA GGA CGA 272 bp
-actin (3′) CTC TCC CTT AGA GGG CAC ACG 450 bp
Altered bases are marked in bold. Degenerate bases: V = A, C or G; Y = C or T.
a Denotes primer altered slightly from the original published sequence; this is also mar
Table 5
Categories used to describe samples in PARR interpretation.
Results Category Deﬁnition
B-cell Clonal ampliﬁcation with one or more IgH primer sets.
T-cell Clonal ampliﬁcation with one or more TCR primer sets.
IgH  and TCR
rearrangement
Clonal ampliﬁcation of similar amplitude with both IgH
and TCR primer sets.
Reactive Polyclonal ampliﬁcation with all PARR primer sets.
Dominant peak
only
Dominant peak seen with one or more PARR primer sets
with no clear clonal peak.
No peak Poor or negative ampliﬁcation with PARR primer sets
alongside good ampliﬁcation of both DNA ampliﬁability
controls. The presence of few lymphocytes in the sample
cannot be distinguished from failure to amplify a clonal
rearrangement.
Inadequate sample Poor or negative ampliﬁcation with one or both DNA
t
p
g
p
b
s
Sampliﬁability controls alongside poor or negative
ampliﬁcation with PARR primer sets.
wo DNA ampliﬁability controls did not work. If no clear clonal or
olyclonal product was detected in such cases, the sample was  cate-
orised as ‘inadequate sample’ since ampliﬁcation of the FWR1 IgH
rimer sets could not be assessed and therefore results could not
e interpreted with conﬁdence. Samples categorised as ‘inadequate
ample’ were excluded from sensitivity and speciﬁcity analyses.
amples were assigned to the ‘dominant peak only’ category if thereked by the sufﬁx ‘a’ in the primer number.
was a clonal peak superimposed on a polyclonal background with
no evidence of a discrete clonal peak using any of the primer sets.
Samples were classiﬁed as ‘no peak’ when the control PCRs had
worked satisfactorily but the individual PCRs either generated no
ampliﬁcation products or showed poor ampliﬁcation; this pattern
is observed in samples which contain few lymphocytes and also in
samples with clonal rearrangements that are not ampliﬁed by the
PARR primers.
3. Results
3.1. Initial results
Using the published primer sets in their original pairings (Tables
S1 and S2), the majority of samples diagnosed as B-cell lymphoma
had detectable clonal IgH rearrangements (73 of 81; 90.1%; see
Table 6). A smaller proportion of the T-cell lymphomas had identi-
ﬁable clonal TCR rearrangements (29 of 39; 74.4%), and only 72.9%
(35 of 48) of lymphoma NOS samples had a detectable clone. Since
these ﬁndings suggested that some rearrangements, particularly of
TCR, were being missed a systematic review of the primer sets was
undertaken to try and improve sensitivity, as described in Materials
and Methods. After minor modiﬁcations to the primer sequences
and rationalisation of use of the highly similar J1-2 primers, 14
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Table 6
PARR results by diagnosis.
Diagnosis PARR Result
B-cell T-cell Both Reactive DP only No peak Inadequate sample Total
B-cell lymphoma/leukaemia 73a 0 2 2 4 0 0 81
T-cell  lymphoma/leukaemia 1 38 0 0 1 0 5 45
Lymphoma/leukaemia NOS 20 20 0 4 3 1 5 53
Null-cell lymphoma 1 2 0 2 0 1 0 6
Double-labelled lymphoma 0 0 0 0 0 1 0 1
Plasma cell tumour 2 0 0 0 0 1 0 3
CD34-positive leukaemia 0 3 0 3 0 0 0 6
Reactive/inﬂammatory 0 0 0 46 7 0 0 53
Other  neoplasia 1 0 0 10 6 5 1 23
Total  98 63 2 67 21 9 11 271
Both: clonal IgH and TCR rearrangement; DP: dominant peak. See Table 5 for deﬁnition 
a Includes two samples where a clone was  detected using only the extra primer set 11 
Fig. 3. PARR electropherogram showing poor ampliﬁcation. (For interpretation of
the  references to colour in this ﬁgure legend, the reader is referred to the web version
of  this article.)
Size markers are shown in red. This sample has ampliﬁed poorly, generating a small
number of low amplitude peaks using both primer sets 1 (blue) and 4 (green). The
lack  of a Gaussian distribution of fragments or a clonal peak suggests that only a
small number of cells in the sample contained rearranged IgH genes. This sample was
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(lassiﬁed in the ‘no peak’ category, as the result suggests that either few lymphoid
ells were present in the sample or that a clonal rearrangement was  present but was
ot detected using these primers.
rimer sets were selected; ten primer sets were included in our
tandard panel (Table 3) and four sets formed an additional panel
Table 4).
.2. Final results
Following primer review, samples with no clear clonal result
ere further analysed using the new primer set combinations (IgH
et 6, TCR sets 8 and 10) and with TCR primer set 9 using the
ew thermal cycling conditions. Samples previously designated as
reactive’, ‘inadequate sample’, ‘no peak’, or ‘dominant peak only’
ere assayed. Since further testing was not performed on samples
hat had a clear clonal result, each sample was not tested with every
rimer set. All samples submitted following primer review were
ested with the standard panel of ten primer sets (six IgH and four
CR, Table 3). If a clear clonal result was still not detected, samples
ere further tested using the four additional primer sets (two IgH
nd two TCR, Table 4). All 271 samples were assigned to a ﬁnal
esults category (Table 6).
Eleven out of the two hundred and seventy one samples (Table 6)
ere designated ‘inadequate sample’ and excluded from further
nalysis based on poor or no ampliﬁcation with at least one ampliﬁ-
ation control and the PARR primers. After primer modiﬁcation, one
dditional ‘inadequate sample’ was reclassiﬁed, since primer set 9
enerated a clonal TCR product using the new cycling conditions
negative using previous conditions). Ampliﬁcation of a speciﬁcof PARR results categories.
(916/915a), not part of the routine PARR protocol.
TCR product was conﬁrmed by sequencing (data not shown). Of
the remaining 260 samples, 163 (62.7%) had a clear clonal result and
67 (25.8%) were clearly polyclonal. Nine samples (3.5%) had poor
or negative ampliﬁcation with all PARR primer sets despite good
ampliﬁcation with the control primers (Fig. 3), suggesting that the
samples contained few lymphocytes or a clonal rearrangement had
been missed, while 21 samples (8.1%) had one or more dominant
peaks (Fig. 2) with no clear evidence of clonality.
Introduction of the modiﬁed primer sets led to re-categorisation
of 17 (6.3%) samples. Fifteen of these samples had detectable clonal
TCR rearrangements (Fig. 4), and were previously classiﬁed as
‘reactive’ (n = 8), ‘dominant peak only’ (n = 4), ‘no peak’ (n = 2) or
‘inadequate sample’ (n = 1, as described above). All TCR clones
were detected using primer sets in the standard panel, however in
two samples a clearer clonal peak was  generated using additional
primer sets 13 or 14. The remaining two re-categorised samples
had clonal IgH rearrangements detected using additional primer
set 11; these cases had previously been classiﬁed as ‘reactive’ and
‘dominant peak only’.
3.3. Comparison with morphological diagnosis
Final results were then compared with the diagnosis reached on
the basis of morphology. Results were clearly discordant in 12 sam-
ples (4.6%). There was  one false positive result; a patient diagnosed
with myeloid neoplasia had clonal peaks detected using two IgH
primer sets. The clonal result was repeatable using the same sam-
ple (lymph node); however, fresh samples from both lymph node
and bone marrow yielded polyclonal results. Concurrent cytol-
ogy indicated that the lymph node contained a high proportion of
myeloid precursors amidst a background of mature lymphoid cells.
Eleven samples were diagnosed as lymphoid malignancy but had a
polyclonal PARR result and could represent false negative results.
These comprised two  splenic B-cell lymphomas, four lymphoma
NOS samples, two  null-cell lymphomas, and three CD34-positive
leukaemias. All four ‘diagnoses’ were over-represented in this
group compared with the overall sample distribution. A further 12
samples diagnosed as lymphoid malignancy had equivocal PARR
results: eight were ‘dominant peak only’ and four were categorised
as ‘no peak’.
Overall, 160 of 185 samples with a diagnosis of lymphoid malig-
nancy produced a clonal result (B-cell, T-cell or both) with the
standard panel of ten primer sets, or 162 of 185 samples when
the additional primer sets were included. This gives sensitivities of
86.5% and 87.6%, respectively. Speciﬁcity was 98.7%, based on the
absence of clonal IgH or TCR rearrangement in 74 of 75 samples
with conditions other than lymphoid malignancy.
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Fig. 4. PARR electropherograms of a T-cell lymphoma. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this
article.)
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lize  markers are shown in red. A: Original primer sets. This sample was designate
hown (blue). B: Final primer sets. Clonal product detected using one of the TCR pr
efer  to the TCR V and J segments ampliﬁed by the primer set (see Table 3).
.4. Concordance between immunophenotype and genotype
Conclusive immunophenotyping results were available for 139
f 195 lymphoid malignancy cases (Table 1). Of these, 126 had a
eﬁned B- or T-cell immunophenotype, which allowed a direct
omparison with the PARR genotype. A clonal PARR result was
enerated in 112 (88.9%) of these samples; the remaining 14 sam-
les yielded either polyclonal or equivocal results (Table 6). In 109
f the 112 clonal samples (97%), PARR genotype was concordant
ith the recorded immunophenotype. In three samples there was
otential evidence of cross-lineage rearrangement. One sample
iagnosed as T-cell lymphoma by IHC had a clonal rearrangement
etected using three IgH primer sets, suggesting a B-cell origin.
ll TCR primer sets yielded polyclonal products. The diagnosis of
on-epitheliotropic cutaneous T-cell lymphoma was  based on CD3
ositivity, but approximately 50% of the inﬁltrating cells did not
tain with CD3 or PAX5 antibodies and could have represented
 neoplastic population of B-cells with clonal IgH rearrangement
nd down-regulation of PAX5. Material was not available for fur-
her IHC analysis with CD79a antibody, or repeat DNA extraction
nd PARR analysis. Two samples diagnosed as B-cell lymphoma by
HC had clonal results using both IgH and TCR primer sets, and
o a deﬁnitive lineage could not be assigned using PARR. While
n both samples a small polyclonal background was present, the
lonal peaks generated with the TCR primer sets were of sufﬁ-
ient amplitude that both samples could have been diagnosed as
-cell lymphoma had no concurrent IgH peaks been present and
ad the IHC not been performed.
.5. Lineage classiﬁcation determined by PARR
Six samples were classiﬁed as B- or T-cell lineage using PARR
here there was no clearly deﬁned B- or T-cell population following
mmunophenotyping. Of these, three were diagnosed as null-cell
non-B, non-T) lymphoma by IHC and PARR identiﬁed one as a
-cell and two as T-cell tumours. Similarly three samples classi-
ed as CD34-positive leukaemia with dim or negative staining for
eukocyte antigens on FC were assigned to a T-cell lineage by PARR.active due to polyclonal ampliﬁcation using the TCR primer sets. Primer set 7 is
ets added in the ﬁnal protocol (primer set 10; green). V2&6, Jx-2, V3&5&7 and Jx-1
Lineage was also assigned to the ﬁve samples previously designated
as lymphoma NOS where FC was inconclusive.
4. Discussion
The aim of this study was  to develop a panel of PARR assays for
routine use in the diagnostic setting. As a starting point we used
PCR assays previously described in the literature but later modiﬁed
some of the primer sequences, rationalised the use of highly sim-
ilar primers, and adapted the thermal cycling parameters to allow
use of a minimum number of different conditions. These changes
improved the ability to detect clonal rearrangements, particularly
in T-cell malignancies. We describe a ‘standard’ panel of ten primer
pairs, recommended for routine use. These comprise six IgH and
four TCR primer sets, which will pick up the vast majority of rear-
rangements. A further four additional primer pairs are described
that are useful in certain circumstances.
Comparison with morphological diagnoses suggested that the
sensitivity of this PARR panel was  86.5%, which is within the range
(80–97.9%) described elsewhere (Burnett et al., 2003; Gentilini
et al., 2009; Chaubert et al., 2010; Keller and Moore, 2012). How-
ever, previous studies have generally used samples from known
cases of lymphoma, excluding samples without a conﬁrmed diag-
nosis and sometimes also lymphoid leukaemias and plasma cell
tumours (Burnett et al., 2003; Gentilini et al., 2009). In particular,
samples from other neoplastic conditions have often been avoided,
despite the fact that lymphoma may  be a differential diagnosis in
many of these cases. By contrast, this case series was  composed of
unselected diagnostic samples from a wide range of source materi-
als, to assess the usefulness of PARR in routine diagnostic practice.
Assay sensitivity improved as more primer sets were included,
offset by increased cost of labour and reagents. We believe that the
standard protocol described here is a good compromise between
sensitivity and ease of use and has improved sensitivity over pre-
vious studies using fewer primer sets (Burnett et al., 2003; Tamura
et al., 2006; Chaubert et al., 2010). Retaining singleplex reactions
avoids difﬁculties in interpretation and should allow detection of
smaller clonal populations; using multiple primer sets also pro-
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ides redundancy should mutation alter any primer binding site.
n part, the number of primer sets in the standard panel was cho-
en for practicality, as with multiplexing at the analysis stage this
llowed the use of a single column of a 96-well plate per sample in
he GeneScan analysis. The additional primer sets increased overall
ensitivity slightly, but not enough to justify the added expense of
unning them routinely. Instead, these primer combinations were
eserved for samples where no clone was detected but there was
 high index of suspicion for lymphoma. Samples with a dominant
eak may  also warrant the use of the additional sets, particularly
here the dominant peak is detected using primer 929 (primer sets
 and 10) as this shares similarities with primer 931 (additional
rimer sets 13 and 14).
There are several plausible explanations for our failure to detect
lonal rearrangements in samples with a morphological diagnosis
f lymphoma. One obvious concern is that the primers used do not
ind to the rearranged gene segments (Valli et al., 2006; O’Brien
t al., 2013). Analysis of the described functional V and J segments
f IgH and TCR indicates that there are few gaps in coverage. Fail-
re of primer binding is therefore more likely to be due to somatic
ypermutation. Certain diagnoses were clearly over-represented
n this group of samples, including splenic B-cell lymphoma, null
ell lymphoma and CD34-positive leukaemia. Sampling error lead-
ng to masking of a focal neoplastic lesion by a polyclonal signal
n an organ rich in normal lymphocytes may  explain the over-
epresentation of splenic B-cell lymphomas (Burnett et al., 2003).
n null cell lymphomas and CD34-positive leukaemias there may  be
 genuine absence of IgH or TCR loci rearrangements since null-
ell lymphomas may  actually be NK cell tumours (van Dongen et al.,
003; Ponce et al., 2010), and CD34-positive leukaemias may repre-
ent expansions of immature B-cells that have not completed V(D)J
ecombination. This would appear as ‘no peak’ when most cells are
on-B-, non-T-cells, or as a polyclonal result when residual reactive
- and T-cells are present. In all these cases, consideration should
lso be given to the accuracy of the original diagnosis. Although the
ytological or histological diagnosis was regarded as deﬁnitive for
he purposes of this analysis, arriving at the most accurate diagnosis
equires consideration of all available diagnostic tests.
False positive results were rare (1 of 75), giving a speciﬁcity of
8.7%. Clonal IgH peaks were detected in a sample from a myeloid
eoplasia. Although rearrangement of IgH has been documented
n human and canine acute myeloid leukaemia (Cheng et al., 1986;
yoda et al., 1997), it is possible that the clonal products in this sam-
le resulted from sampling error, since repeated testing of fresh
amples gave polyclonal results (Elenitoba-Johnson et al., 2000;
ienzle and Vernau, 2011; Langerak et al., 2012). For cost reasons,
e do not routinely perform testing of samples in duplicate as has
een recommended (Keller et al., 2016) but where pseudoclonality
s suspected or PARR gives unexpected results repeat testing of the
ame or additional samples should be performed.
Despite the use of routine diagnostic samples, only 11 of 271
4%) samples were classiﬁed as inadequate. With one exception,
hese samples were extracted from FFPE material, which is likely
o have contained more degraded DNA than the fresh tissue (van
ongen et al., 2003), or may  have contained PCR inhibitors (An and
leming, 1991). Nevertheless, ﬁxed material generally performed
ell, with 79 FFPE and nine ﬁxed smear samples producing ampli-
able DNA.
Five of the nine samples placed in the ‘no peak’ category were
rom patients with non-lymphoid neoplasia, consistent with the
ARR result. Two samples with clonal T-cell peaks were identi-
ed using only the new, modiﬁed primer sets and had previously
een categorised as ‘no peak’. Results must be interpreted along-
ide ﬁndings using other diagnostic modalities and if this pattern
s seen in samples where there is a high index of suspicion of lym- Immunopathology 182 (2016) 115–124
phoma, repeat sampling and use of additional PARR primer sets are
recommended.
Perhaps the most problematic samples to interpret were those
in the ‘dominant peak only’ category, with direct impact on over-
all assay sensitivity. Most previous reports either do not mention
this phenomenon, or infer that all such results indicate clonality
(Burnett et al., 2003; Lana et al., 2006; Gentilini et al., 2009). Keller
and Moore (2012) deﬁned any dominant peak with a peak height at
least twice as tall as the polyclonal background as signiﬁcant. Using
this deﬁnition all ‘dominant peak only’ samples in this series would
have been classiﬁed as clonal, increasing sensitivity to 97.6% but
with a concomitant drop in speciﬁcity to 84.3%. These results lead
us to concur with the recommendation made in a recent review of
PARR (Keller et al., 2016), which concludes that mathematical algo-
rithms such as this cannot be used to aid interpretation of PARR
results.
Dominant peaks were often observed in samples with a clear
clonal peak detected with another primer set, suggesting that
primer mismatches, most probably resulting from somatic hyper-
mutation, can give rise to this pattern on electropherograms. This
again emphasises the beneﬁt of using multiple primer sets, includ-
ing the additional primer sets when there is a high index of
suspicion. A dominant peak may  also indicate a small clonal popula-
tion of cells within a background of reactive lymphocytes (Gentilini
et al., 2009; Keller and Moore, 2012) either in early neoplasia, or as
feature of particular tumours where neoplastic cells do not replace
the whole organ, such as splenic marginal zone lymphoma (SMZL).
Here, this could be seen in two  samples of SMZL and one of low-
grade lymphoma which generated dominant peaks using at least
one IgH primer set.
Dominant peaks could also result from antigenic stimulation
occurring during infection or inﬂammatory reactions, as seen in
seven reactive/inﬂammatory samples in this series. Non-neoplastic
clonal proliferations have been documented in humans (Posnett
et al., 1994; Billadeau et al., 1996) and in dogs, where infection with
Ehrlichia species may  generate clonal PARR results (Burnett et al.,
2003). One reactive sample classed as ‘dominant peak only’ was  a
dog with suspected tick-borne disease; unfortunately there was no
opportunity to test a second sample from this dog post-treatment.
Follow-up and repeat sampling of patients with samples displaying
dominant peaks may  be required to help establish their signiﬁ-
cance, particularly in cases where an inﬂammatory lesion could
progress to overt lymphoma, such as inﬂammatory bowel disease.
In one T-cell lymphoma, a dominant peak of the opposite genotype
(IgH) was the only evidence of clonality while for two  other lym-
phomas with similar dominant peak results, a clone of the ‘correct’
genotype was  detected only after using the additional primer sets.
Cross-lineage dominant peaks were also seen in 17 samples with a
clonal result (11 B-cell and six T-cell). While sampling error lead-
ing to pseudoclonality could account for some of these results, they
may  also be due to a restricted antigenic response to the neoplastic
cells.
The agreement between PARR and previous immunophenotype
was excellent (97%). Two of three discordant samples had clonal
rearrangements of both IgH and TCR, which has been documented
previously in canine and human lymphoid tumours (Burnett et al.,
2003; Tan et al., 2006; Valli et al., 2006; Bagg, 2006). In humans,
the clonal rearrangements may  arise from separate populations of
cells. In T-cell tumours, a clonal B-cell population may arise sec-
ondary to immune dysfunction, usually in association with EBV
infection (Luzzatto et al., 2005; Tan et al., 2006) and transform to
produce a tumour containing malignant B- and T-cells (Zettl et al.,
2002). In B-cell tumours, a restricted T-cell response may  generate
clonal TCR rearrangements (Sze, 2005). Alternatively, IgH and TCR
rearrangements may  occur in the same early precursor cell (Bagg,
2006).
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In this case series, PARR proved useful for assigning lineage
here other methods were inconclusive. A previous study reported
hat FC more accurately determines lineage (Thalheim et al., 2013);
owever, fewer PARR primer sets were used in the latter study,
otentially limiting assay sensitivity. Where surface antigens are
own-regulated, or the malignant cell population is not the most
umerous in the sample (for example T-cell-rich B-cell lymphoma),
ARR will deﬁne lineage more accurately than FC. While previous
tudies have suggested that PARR should not be used as a means
f assigning cell lineage because of problems with cross-lineage
earrangement, our results indicate that clonal cross-lineage rear-
angement was rare in this case series. We  would suggest that
here other modalities for immunophenotyping are not available,
ARR is an appropriate tool for lineage determination.
. Conclusions
The combination of primer sets used in this protocol resulted in
 robust, highly sensitive and speciﬁc assay. Although PARR pro-
ides diagnostic information unavailable from other tests and can
elp determine tumour lineage where other techniques have failed,
nterpretation of results must consider clinical presentation, cell
orphology, immunophenotype and other ancillary tests. Knowl-
dge of sample quality is essential, as samples with few cells or
oor quality DNA will likely amplify poorly, giving an equivocal
esult. Dominant peaks, which may  indicate a neoplastic population
ithin a reactive background, but are also seen in non-lymphoma
amples, pose a particular challenge. Better understanding of the
ature of these peaks may  come from longer term follow-up of
ases and sequencing of products. Further investigation of these
ndings will improve the precision of this important diagnostic
est.
cknowledgements
EW is supported by the Biotechnology and Biological Sciences
esearch Council, grant number BB/F016786/1, with additional
unding from Novartis Animal Health. Data are available from the
orresponding author on request. We  would like to thank the
linicians of the University of Glasgow Small Animal Hospital for
ssistance with sample collection, and the staff of Veterinary Diag-
ostic Services, University of Glasgow, for assistance with sample
rocessing
ppendix A. Supplementary data
Supplementary data associated with this article can be found, in
he online version, at http://dx.doi.org/10.1016/j.vetimm.2016.10.
08.
eferences
n, S.F., Fleming, K.A., 1991. Removal of inhibitor(s) of the polymerase chain
reaction from formalin ﬁxed: parafﬁn wax embedded tissues. J. Clin. Pathol. 44,
924–927.
very, A., 2009. Molecular diagnostics of hematologic malignancies. Top.
Companion Anim. Med. 24, 144–150.
agg, A., 2006. Immunoglobulin and T-cell receptor gene rearrangements: minding
your B’s and T’s in assessing lineage and clonality in neoplastic
lymphoproliferative disorders. J. Mol. Diagn. 8, 426–429.
ao, Y., Guo, Y., Xiao, S., Zhao, Z., 2010. Molecular characterization of the VH
repertoire in Canis familiaris. Vet. Immunol. Immunopathol. 137, 64–75.
ienzle, D., Vernau, W.,  2011. The diagnostic assessment of canine lymphoma:
implications for treatment. Clin. Lab. Med. 31, 21–39.illadeau, D., van Ness, B., Kimlinger, T., Kyle, R.A., Therneau, T.M., Greipp, P.R.,
Witzig, T.E., 1996. Clonal circulating cells are common in plasma cell
proliferative disorders: a comparison of monoclonal gammopathy of
undetermined signiﬁcance smoldering multiple myeloma, and active
myeloma. Blood 88, 289–296. Immunopathology 182 (2016) 115–124 123
Burnett, R.C., Vernau, W.,  Modiano, J.F., Olver, C.S., Moore, P.F., Avery, A.C., 2003.
Diagnosis of canine lymphoid neoplasia using clonal rearrangements of
antigen receptor genes. Vet. Pathol. 40, 32–41.
Chaubert, P., Baur Chaubert, A.S., Sattler, U., Forster, U.,  Bornand, V., Suter, M.,
Welle, M.,  2010. Improved polymerase chain reaction-based method to detect
early-stage epitheliotropic T-cell lymphoma (mycosis fungoides) in
formalin-ﬁxed, parafﬁn-embedded skin biopsy specimens of the dog. J. Vet.
Diagn. Invest. 22, 20–29.
Cheng, G.Y., Minden, M.D., Toyonaga, B., Mak, T.W., McCulloch, E.A., 1986. T cell
receptor and immunoglobulin gene rearrangements in acute myeloblastic
leukemia. J. Exp. Med. 163, 414–424.
Elenitoba-Johnson, K.S., Bohling, S.D., Mitchell, R.S., Brown, M.S., Robetorye, R.S.,
2000. PCR analysis of the immunoglobulin heavy chain gene in polyclonal
processes can yield pseudoclonal bands as an artifact of low B cell number. J.
Mol. Diagn. 2, 92–96.
Gentilini, F., Calzolari, C., Turba, M.E., Bettini, G., Famigli-Bergamini, P., 2009.
GeneScanning analysis of Ig/TCR gene rearrangements to detect clonality in
canine lymphomas. Vet. Immunol. Immunopathol. 127, 47–56.
Keller, S.M., Moore, P.F., 2012. A novel clonality assay for the assessment of canine
T  cell proliferations. Vet. Immunol. Immunopathol. 145, 410–419.
Keller, S.M., Vernau, W.,  Moore, P.F., 2016. Clonality testing in veterinary medicine:
a  review with diagnostic guidelines. Vet. Pathol. 53 (4), 711–725.
Kyoda, K., Nakamura, S., Matano, S., Ohtake, S., Matsuda, T., 1997. Prognostic
signiﬁcance of immunoglobulin heavy chain gene rearrangement in patients
with acute myelogenous leukemia. Leukemia 11, 803–806.
Lana, S.E., Jackson, T.L., Burnett, R.C., Morley, P.S., Avery, A.C., 2006. Utility of
polymerase chain reaction for analysis of antigen receptor rearrangement in
staging and predicting prognosis in dogs with lymphoma. J. Vet. Intern. Med.
20, 329–334.
Langerak, A.W., Groenen, P.J., Bruggemann, M.,  Beldjord, K., Bellan, C., Bonello, L.,
Boone, E., Carter, G.I., Catherwood, M.,  Davi, F., Delfau-Larue, M.H., Diss, T.,
Evans, P.A., Gameiro, P., Garcia, S.R., Gonzalez, D., Grand, D., Hakansson, A.,
Hummel, M.,  Liu, H., Lombardia, L., Macintyre, E.A., Milner, B.J.,
Montes-Moreno, S., Schuuring, E., Spaargaren, M.,  Hodges, E., van Dongen, J.J.,
2012. EuroClonality/BIOMED-2 guidelines for interpretation and reporting of
Ig/TCR clonality testing in suspected lymphoproliferations. Leukemia 26,
2159–2171.
Lindblad-Toh, K., Wade, C.M., Mikkelsen, T.S., Karlsson, E.K., Jaffe, D.B., Kamal, M.,
Clamp, M.,  Chang, J.L., Kulbokas III, E.J., Zody, M.C., Mauceli, E., Xie, X., Breen, M.,
Wayne, R.K., Ostrander, E.A., Ponting, C.P., Galibert, F., Smith, D.R., DeJong, P.J.,
Kirkness, E., Alvarez, P., Biagi, T., Brockman, W.,  Butler, J., Chin, C.W., Cook, A.,
Cuff, J., Daly, M.J., DeCaprio, D., Gnerre, S., Grabherr, M.,  Kellis, M., Kleber, M.,
Bardeleben, C., Goodstadt, L., Heger, A., Hitte, C., Kim, L., Koepﬂi, K.P., Parker,
H.G., Pollinger, J.P., Searle, S.M., Sutter, N.B., Thomas, R., Webber, C., Baldwin, J.,
Abebe, A., Abouelleil, A., Aftuck, L., Ait-Zahra, M.,  Aldredge, T., Allen, N., An, P.,
Anderson, S., Antoine, C., Arachchi, H., Aslam, A., Ayotte, L., Bachantsang, P.,
Barry, A., Bayul, T., Benamara, M.,  Berlin, A., Bessette, D., Blitshteyn, B., Bloom,
T.,  Blye, J., Boguslavskiy, L., Bonnet, C., Boukhgalter, B., Brown, A., Cahill, P.,
Calixte, N., Camarata, J., Cheshatsang, Y., Chu, J., Citroen, M.,  Collymore, A.,
Cooke, P., Dawoe, T., Daza, R., Decktor, K., DeGray, S., Dhargay, N., Dooley, K.,
Dooley, K., Dorje, P., Dorjee, K., Dorris, L., Duffey, N., Dupes, A., Egbiremolen, O.,
Elong, R., Falk, J., Farina, A., Faro, S., Ferguson, D., Ferreira, P., Fisher, S.,
FitzGerald, M.,  et al., 2005. Genome sequence: comparative analysis and
haplotype structure of the domestic dog. Nature 438, 803–819.
Luzzatto, F., Pruneri, G., Benini, E., Manzotti, M.,  Laszlo, D., Martinelli, G., Viale, G.,
2005. Angioimmunoblastic T-cell lymphoma with hyperplastic germinal
centres and a high content of EBV-infected large B-cells carrying IgH chain
gene monoclonal rearrangement. Histopathology 46, 464–466.
Massari, S., Bellahcene, F., Vaccarelli, G., Carelli, G., Mineccia, M.,  Lefranc, M.P.,
Antonacci, R., Ciccarese, S., 2009. The deduced structure of the T cell receptor
gamma  locus in Canis lupus familiaris. Mol. Immunol. 46, 2728–2736.
O’Brien, D., Moore, P.F., Vernau, W.,  Peauroi, J.R., Rebhun, R.B., Rodriguez Jr., C.O.,
Skorupski, K.A., 2013. Clinical characteristics and outcome in dogs with splenic
marginal zone lymphoma. J. Vet. Intern. Med. 27, 949–954.
Ponce, F., Marchal, T., Magnol, J.P., Turinelli, V., Ledieu, D., Bonnefont, C., Pastor, M.,
Delignette, M.L., Fournel-Fleury, C., 2010. A morphological study of 608 cases of
canine malignant lymphoma in France with a focus on comparative similarities
between canine and human lymphoma morphology. Vet. Pathol. 47, 414–433.
Posnett, D.N., Sinha, R., Kabak, S., Russo, C., 1994. Clonal populations of T cells in
normal elderly humans: the T cell equivalent to benign monoclonal
gammapathy. J. Exp. Med. 179, 609–618.
Stadhouders, R., Pas, S.D., Anber, J., Voermans, J., Mes, T.H., Schutten, M.,  2010. The
effect of primer-template mismatches on the detection and quantiﬁcation of
nucleic acids using the 5’ nuclease assay. J. Mol. Diagn. 12, 109–117.
Sze, D.M., 2005. Clonality detection of expanded T-cell populations in patients
with multiple myeloma. Methods Mol. Med. 113, 257–267.
Tamura, K., Yagihara, H., Isotani, M.,  Ono, K., Washizu, T., Bonkobara, M.,  2006.
Development of the polymerase chain reaction assay based on the canine
genome database for detection of monoclonality in B cell lymphoma. Vet.
Immunol. Immunopathol. 110, 163–167.
Tan, B.T., Warnke, R.A., Arber, D.A., 2006. The frequency of B- and T-cell gene
rearrangements and epstein-barr virus in T-cell lymphomas: a comparison
between angioimmunoblastic T-cell lymphoma and peripheral T-cell
lymphoma, unspeciﬁed with and without associated B-cell proliferations. J.
Mol. Diagn. 8, 466–475.
1 gy and
T
V
v Immunopathol. 115, 375–382.
Zettl, A., Lee, S.S., Rudiger, T., Starostik, P., Marino, M.,  Kirchner, T., Ott, M.,
Muller-Hermelink, H.K., Ott, G., 2002. Epstein-Barr virus-associated B-cell24 E.M. Waugh et al. / Veterinary Immunolo
halheim, L., Williams, L.E., Borst, L.B., Fogle, J.E., Suter, S.E., 2013. Lymphoma
immunophenotype of dogs determined by immunohistochemistry ﬂow
cytometry, and polymerase chain reaction for antigen receptor
rearrangements. J. Vet. Intern. Med. 27, 1509–1516.
alli, V.E., Vernau, W.,  de Lorimier, L.P., Graham, P.S., Moore, P.F., 2006. Canine
indolent nodular lymphoma. Vet. Pathol. 43, 241–256.
an Dongen, J.J., Langerak, A.W., Bruggemann, M.,  Evans, P.A., Hummel, M.,
Lavender, F.L., Delabesse, E., Davi, F., Schuuring, E., Garcia-Sanz, R., van Krieken,
J.H., Droese, J., Gonzalez, D., Bastard, C., White, H.E., Spaargaren, M.,  Gonzalez,
M.,  Parreira, A., Smith, J.L., Morgan, G.J., Kneba, M.,  Macintyre, E.A., 2003.
Design and standardization of PCR primers and protocols for detection of
clonal immunoglobulin and T-cell receptor gene recombinations in suspect
lymphoproliferations: report of the BIOMED-2 Concerted Action
BMH4-CT98-3936. Leukemia 17, 2257–2317. Immunopathology 182 (2016) 115–124
Vernau, W.,  Moore, P.F., 1999. An immunophenotypic study of canine leukemias
and preliminary assessment of clonality by polymerase chain reaction. Vet.
Immunol. Immunopathol. 69, 145–164.
Yagihara, H., Tamura, K., Isotani, M.,  Ono, K., Washizu, T., Bonkobara, M.,  2007.
Genomic organization of the T-cell receptor gamma gene and PCR detection of
its  clonal rearrangement in canine T-cell lymphoma/leukemia. Vet. Immunol.lymphoproliferative disorders in angloimmunoblastic T-cell lymphoma and
peripheral T-cell lymphoma unspeciﬁed. Am. J. Clin. Pathol. 117, 368–379.
